Three-year Outcomes of Botulinum Toxin Versus Strabismus Surgery for the Treatment of Acute Acquired Comitant Esotropia in Children.

American journal of ophthalmology 2025 Vol.272() p. 1-7

Nguyen MTB, Cheung CSY, Hunter DG, Wan MJ, Gise R

관련 도메인

Abstract

[INTRODUCTION] Botulinum toxin is an alternative to conventional strabismus surgery for treatment of acute, acquired, comitant esotropia (AACE). Previous studies suggest that the 2 treatment approaches may be equally effective for 6 months. The purpose of our study was to determine whether botulinum toxin remains as effective as strabismus surgery for 36 months after treatment.

[DESIGN] Multicenter, retrospective, nonrandomized, comparative, clinical, noninferiority study.

[METHODS] Setting: Two tertiary care pediatric hospitals.

[STUDY POPULATION] 76 children with AACE followed for at least 36 months after treatment.

[INTERVENTION] Treatment with either botulinum toxin ("BTX group") or strabismus surgery ("surgery group").

[MAIN OUTCOME MEASURE] Success rate at 36 months (horizontal deviation of 10 prism diopters or less and evidence of binocular vision).

[RESULTS] There were 44 patients in the BTX group and 32 patients in the surgery group with a median deviation of 35 PD in both groups (range 10-55). The duration of general anesthesia (6 versus 71 min, P < .0001) and time in the postanesthesia care unit (40 versus 95 min, P < .0001) were significantly shorter in the BTX group. At 36 months, the success rate was 72% in the BTX group and 56% in the surgery group with a similar median deviation and median stereoacuity. BTX was noninferior to surgery at 36 months (95%CI for difference in success rate (BTX minus surgery) was -5% to +38%). At 36 months, the median time from esotropia onset to any intervention was 6.5 months without treatment success and 4 months in those with treatment success (P < .05).

[CONCLUSIONS/RELEVANCE] Botulinum toxin was noninferior to strabismus surgery in the treatment of AACE at 36 months while reducing the duration of general anesthesia. Longer delay from esotropia onset to treatment was an independent risk factor for worse sensorimotor outcomes irresepctive of the type of treatment.

추출된 의학 개체 (NER)

유형영어 표현한국어 / 풀이UMLS CUI출처등장
시술 botulinum toxin 보툴리눔독소 주사 dict 5
약물 noninferior scispacy 1
약물 CONCLUSIONS/RELEVANCE scispacy 1
약물 [INTRODUCTION] Botulinum toxin scispacy 1
약물 [DESIGN] scispacy 1
약물 [MAIN OUTCOME MEASURE] scispacy 1
약물 [RESULTS] scispacy 1
약물 BTX scispacy 1
약물 [CONCLUSIONS/RELEVANCE] Botulinum toxin scispacy 1
질환 Strabismus C0038379
Strabismus
scispacy 1
질환 comitant esotropia scispacy 1
질환 binocular vision C0042794
Vision, Binocular
scispacy 1
질환 esotropia C0014877
Esotropia
scispacy 1
질환 BTX scispacy 1
기타 Children scispacy 1
기타 BTX scispacy 1
기타 patients scispacy 1
기타 anesthesia (6 versus 71 scispacy 1

MeSH Terms

Adolescent; Child; Child, Preschool; Female; Humans; Infant; Male; Acute Disease; Botulinum Toxins, Type A; Esotropia; Eye Movements; Follow-Up Studies; Injections, Intramuscular; Neuromuscular Agents; Oculomotor Muscles; Ophthalmologic Surgical Procedures; Retrospective Studies; Treatment Outcome; Vision, Binocular; Visual Acuity

📑 인용 관계

🔗 함께 등장하는 도메인

이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들

관련 논문